Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

Also called NCT01541865

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 146 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01541865
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Austria, Belgium, France, Germany, Netherlands, New Zealand, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01541865. Allocation not applicable; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-11 (actual). Results posted on 2015-10-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
Acronym
REDUCE-HTN
Condition
Hypertension
Intervention (Device)
Renal Denervation
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct01541865
Content hash
807b032b5c4e358944081b82c8f49cbdd765fc5cd28153587cb76d6e4ed81713